Share Price and Basic Stock Data
Last Updated: November 10, 2025, 4:38 pm
| PEG Ratio | -1.82 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dr Lalchandani Labs Ltd operates in the Hospitals & Medical Services sector, with a current market capitalization of ₹10.2 Cr and a share price of ₹23.6. The company has exhibited fluctuating sales trends over recent years, reporting ₹5.04 Cr in sales for the year ending March 2023, a decline from ₹11.28 Cr in March 2022. The company recorded quarterly sales of ₹2.76 Cr in March 2023, followed by ₹2.73 Cr in September 2023, indicating a slight stabilization. However, projected figures for March 2024 and March 2025 show a decline to ₹4.81 Cr and ₹4.45 Cr respectively. This downward trend raises concerns about the company’s revenue generation capabilities and market position. Despite this, the company’s operational profit margin (OPM) stood at 21.89% as of the latest reporting, showing a capacity for profitability amidst declining sales. The overall sales trajectory suggests the need for strategic initiatives to enhance revenue streams and restore growth.
Profitability and Efficiency Metrics
Dr Lalchandani Labs Ltd’s profitability metrics reflect significant challenges, with a net profit of ₹0.42 Cr reported for the year ending March 2025. The company has faced periods of net losses, notably ₹-1.56 Cr in March 2023 and ₹-1.36 Cr in the trailing twelve months (TTM) ending March 2023. The operating profit margin (OPM) has fluctuated, with a low of 1.79% in March 2023, before rebounding to 20.89% in March 2025. The interest coverage ratio (ICR) is a positive indicator at 10.90x, suggesting that the company can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) has expanded significantly to 556.91 days, indicating inefficiencies in managing working capital. Debtor days have also increased to 431.44, showing a potential liquidity risk. Overall, while there are signs of recovery in profit margins, the company needs to address its operational efficiencies to sustain profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dr Lalchandani Labs Ltd reveals a total debt of ₹4.07 Cr against reserves of ₹5.62 Cr, positioning the company to maintain a manageable debt-to-equity ratio of 0.40. The current ratio stands at a healthy 1.92, indicating adequate short-term liquidity to cover liabilities. Additionally, the company has recorded a book value per share of ₹22.98, which is favorable compared to its market price, suggesting potential undervaluation. However, the overall financial health is tempered by the company’s declining return on equity (ROE) of 3.08% and return on capital employed (ROCE) of 2.81%, both of which are low compared to typical sector benchmarks. This indicates that while the company is not heavily leveraged, it is struggling to generate satisfactory returns on its equity and capital. The efficiency in asset utilization, reflected by a low asset turnover ratio of 0.28%, further complicates the financial picture.
Shareholding Pattern and Investor Confidence
As of March 2025, the shareholding pattern of Dr Lalchandani Labs Ltd shows that promoters hold 48.32% of the equity, a decline from 60.78% in previous years. This shift indicates a potential dilution of control by insiders, which may raise concerns among investors regarding future governance and strategic direction. The public shareholding has increased to 51.68%, reflecting growing interest from retail investors. The total number of shareholders has risen significantly to 246, suggesting increased market participation. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) could signal a lack of confidence from larger institutional players, which might affect the company’s ability to attract significant capital. The changing dynamics in the shareholding structure could impact investor sentiment and influence stock performance in the near term.
Outlook, Risks, and Final Insight
The outlook for Dr Lalchandani Labs Ltd is mixed, characterized by both potential and challenges. Strengths include a healthy interest coverage ratio, which indicates financial stability in servicing debt, and a favorable current ratio, suggesting liquidity resilience. However, the company faces significant risks, including declining sales, inefficient working capital management evidenced by an extended cash conversion cycle, and low profitability ratios that may deter investor confidence. To enhance its market position, the company must implement strategies to improve operational efficiency, optimize its inventory management, and innovate its service offerings to stimulate revenue growth. If the company can effectively address these challenges, it may stabilize its financial performance and restore investor confidence. Conversely, prolonged inefficiencies and continued revenue decline could jeopardize its market standing and financial viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dr Lalchandani Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 8.77 Cr. | 20.2 | 28.7/9.80 | 29.2 | 23.0 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 321 Cr. | 163 | 174/72.9 | 22.9 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 36,138 Cr. | 1,768 | 2,372/1,238 | 45.7 | 177 | 0.25 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 236 Cr. | 114 | 141/55.0 | 353 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 12,231.67 Cr | 516.30 | 112.70 | 68.60 | 0.06% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Mar 2019 | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.64 | 3.03 | 3.07 | 2.71 | 7.07 | 8.02 | 3.26 | 2.28 | 2.76 | 2.73 | 2.08 | 2.13 | 2.33 |
| Expenses | 1.95 | 2.30 | 2.53 | 2.14 | 5.40 | 6.07 | 2.81 | 2.46 | 2.50 | 2.38 | 1.04 | 1.59 | 1.82 |
| Operating Profit | 0.69 | 0.73 | 0.54 | 0.57 | 1.67 | 1.95 | 0.45 | -0.18 | 0.26 | 0.35 | 1.04 | 0.54 | 0.51 |
| OPM % | 26.14% | 24.09% | 17.59% | 21.03% | 23.62% | 24.31% | 13.80% | -7.89% | 9.42% | 12.82% | 50.00% | 25.35% | 21.89% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.24 | 0.00 | 0.00 |
| Interest | 0.05 | 0.09 | 0.09 | 0.05 | 0.30 | 0.24 | 0.33 | 0.48 | 0.51 | 0.11 | 0.28 | 0.05 | 0.03 |
| Depreciation | 0.20 | 0.21 | 0.22 | 0.23 | 0.29 | 0.28 | 0.30 | 0.33 | 0.34 | 0.33 | 0.29 | 0.28 | 0.28 |
| Profit before tax | 0.45 | 0.43 | 0.23 | 0.29 | 1.08 | 1.43 | -0.18 | -0.98 | -0.59 | -0.09 | 0.71 | 0.21 | 0.20 |
| Tax % | 26.67% | 0.00% | 82.61% | 24.14% | 27.78% | 25.17% | -22.22% | 0.00% | 0.00% | 0.00% | 0.00% | 23.81% | -35.00% |
| Net Profit | 0.34 | 0.43 | 0.04 | 0.23 | 0.79 | 1.07 | -0.13 | -0.97 | -0.59 | -0.09 | 0.71 | 0.15 | 0.27 |
| EPS in Rs | 0.78 | 0.99 | 0.09 | 0.53 | 1.82 | 2.47 | -0.30 | -2.24 | -1.36 | -0.21 | 1.64 | 0.35 | 0.62 |
Last Updated: May 31, 2025, 6:15 am
Below is a detailed analysis of the quarterly data for Dr Lalchandani Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 2.33 Cr.. The value appears strong and on an upward trend. It has increased from 2.13 Cr. (Sep 2024) to 2.33 Cr., marking an increase of 0.20 Cr..
- For Expenses, as of Mar 2025, the value is 1.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.59 Cr. (Sep 2024) to 1.82 Cr., marking an increase of 0.23 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.51 Cr.. The value appears to be declining and may need further review. It has decreased from 0.54 Cr. (Sep 2024) to 0.51 Cr., marking a decrease of 0.03 Cr..
- For OPM %, as of Mar 2025, the value is 21.89%. The value appears to be declining and may need further review. It has decreased from 25.35% (Sep 2024) to 21.89%, marking a decrease of 3.46%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.05 Cr. (Sep 2024) to 0.03 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.28 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.28 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.20 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Mar 2025, the value is -35.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.81% (Sep 2024) to -35.00%, marking a decrease of 58.81%.
- For Net Profit, as of Mar 2025, the value is 0.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.27 Cr., marking an increase of 0.12 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.62. The value appears strong and on an upward trend. It has increased from 0.35 (Sep 2024) to 0.62, marking an increase of 0.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:29 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 |
| Expenses | 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% |
| Other Income | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.13 |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% |
| Net Profit | 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 |
| EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 0.97 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 103.85% | -11.32% | 114.89% | -7.92% | -267.74% | 139.74% | -32.26% |
| Change in YoY Net Profit Growth (%) | 0.00% | -115.17% | 126.21% | -122.81% | -259.82% | 407.49% | -172.00% |
Dr Lalchandani Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -27% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -23% |
| TTM: | 155% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 0% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:16 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Diluted EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Cash EPS (Rs.) | 2.27 | 2.87 | -2.08 | 3.51 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.98 | 21.98 | 20.56 | 24.16 | 22.01 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.98 | 22.02 | 20.59 | 24.20 | 22.04 |
| Revenue From Operations / Share (Rs.) | 10.28 | 11.10 | 11.63 | 26.03 | 22.57 |
| PBDIT / Share (Rs.) | 2.15 | 1.00 | 0.20 | 5.55 | 5.12 |
| PBIT / Share (Rs.) | 0.84 | -0.43 | -1.33 | 4.20 | 3.93 |
| PBT / Share (Rs.) | 0.92 | 1.43 | -3.61 | 2.97 | 3.18 |
| Net Profit / Share (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| PBDIT Margin (%) | 20.89 | 9.04 | 1.75 | 21.33 | 22.68 |
| PBIT Margin (%) | 8.22 | -3.93 | -11.40 | 16.12 | 17.41 |
| PBT Margin (%) | 9.03 | 12.83 | -31.00 | 11.41 | 14.08 |
| Net Profit Margin (%) | 9.36 | 12.83 | -31.00 | 8.27 | 10.34 |
| Return on Networth / Equity (%) | 4.18 | 6.48 | -17.54 | 8.91 | 10.60 |
| Return on Capital Employeed (%) | 3.63 | -1.89 | -4.63 | 13.71 | 13.81 |
| Return On Assets (%) | 2.64 | 4.11 | -8.82 | 5.14 | 6.65 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.37 | 0.25 | 0.27 |
| Total Debt / Equity (X) | 0.40 | 0.35 | 0.52 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.28 | 0.29 | 0.28 | 0.67 | 0.72 |
| Current Ratio (X) | 1.92 | 1.88 | 2.07 | 2.22 | 2.98 |
| Quick Ratio (X) | 1.69 | 1.60 | 1.78 | 1.90 | 2.75 |
| Inventory Turnover Ratio (X) | 0.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 10.90 | 1.13 | 0.08 | 4.52 | 6.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | -0.49 | -0.58 | 2.75 | 4.10 |
| Enterprise Value (Cr.) | 5.20 | 7.92 | 13.89 | 14.81 | 6.53 |
| EV / Net Operating Revenue (X) | 1.17 | 1.65 | 2.76 | 1.31 | 0.66 |
| EV / EBITDA (X) | 5.59 | 18.19 | 157.32 | 6.15 | 2.94 |
| MarketCap / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| Price / BV (X) | 0.44 | 0.71 | 1.38 | 1.37 | 0.63 |
| Price / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| EarningsYield | 0.09 | 0.09 | -0.12 | 0.06 | 0.16 |
After reviewing the key financial ratios for Dr Lalchandani Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 3. It has decreased from 2.87 (Mar 24) to 2.27, marking a decrease of 0.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.98. It has increased from 21.98 (Mar 24) to 22.98, marking an increase of 1.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.98. It has increased from 22.02 (Mar 24) to 22.98, marking an increase of 0.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.28. It has decreased from 11.10 (Mar 24) to 10.28, marking a decrease of 0.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 2.15, marking an increase of 1.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.84. This value is within the healthy range. It has increased from -0.43 (Mar 24) to 0.84, marking an increase of 1.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.92. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 0.92, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 2. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For PBDIT Margin (%), as of Mar 25, the value is 20.89. This value is within the healthy range. It has increased from 9.04 (Mar 24) to 20.89, marking an increase of 11.85.
- For PBIT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has increased from -3.93 (Mar 24) to 8.22, marking an increase of 12.15.
- For PBT Margin (%), as of Mar 25, the value is 9.03. This value is below the healthy minimum of 10. It has decreased from 12.83 (Mar 24) to 9.03, marking a decrease of 3.80.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. It has decreased from 12.83 (Mar 24) to 9.36, marking a decrease of 3.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 15. It has decreased from 6.48 (Mar 24) to 4.18, marking a decrease of 2.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.63. This value is below the healthy minimum of 10. It has increased from -1.89 (Mar 24) to 3.63, marking an increase of 5.52.
- For Return On Assets (%), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 2.64, marking a decrease of 1.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.40, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.28. It has decreased from 0.29 (Mar 24) to 0.28, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 1.92, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.69, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.70, marking an increase of 0.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.90. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 10.90, marking an increase of 9.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from -0.49 (Mar 24) to 4.46, marking an increase of 4.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5.20. It has decreased from 7.92 (Mar 24) to 5.20, marking a decrease of 2.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.17. This value is within the healthy range. It has decreased from 1.65 (Mar 24) to 1.17, marking a decrease of 0.48.
- For EV / EBITDA (X), as of Mar 25, the value is 5.59. This value is within the healthy range. It has decreased from 18.19 (Mar 24) to 5.59, marking a decrease of 12.60.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For Price / BV (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 24) to 0.44, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.09.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lalchandani Labs Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.63% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.18% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.2 (Industry average Stock P/E: 112.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.4
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | M-20, Basement, Greater Kailash, New Delhi Delhi 110048 | info@lalchandanipathlab.com www.lalchandanipathlab.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Arjan Lal Chandani | Chairman & Managing Director |
| Mr. Mohit Lal Chandani | WholeTime Director & CEO |
| Mrs. Anchal Gupta | Executive Director & CFO |
| Mrs. Swati Chandra | Non Executive Director |
| Mr. Rajiv Handa | Independent Director |
| Mr. Prakash Jhuraney | Independent Director |